## **Supplementary Material**

COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

Jonas Björk<sup>1,2</sup>, Carl Bonander<sup>3</sup>, Mahnaz Moghaddassi<sup>4</sup>, Magnus Rasmussen<sup>5</sup>, Ulf Malmqvist<sup>2</sup>, Malin Inghammar<sup>5</sup>, Fredrik Kahn<sup>5</sup>

<sup>1</sup>Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden

<sup>2</sup>Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden

<sup>3</sup>School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Sweden

<sup>4</sup>Social Medicine and Global Health, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

<sup>5</sup>Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden

## **Content**

Supplementary Table S1 Supplementary Table S2 Supplementary Table S3

## Supplementary Table S1. Routine sequencing of samples of infected cases in Scania county, Sweden.

Year	2021	2022										
Week	52	1	2	3	4	5	6	7	8	9	10	11
Total	289	325	281	340	288	314	314	222	222	123	124	157
Omicron BA.1	162	206	136	153	72	65	40	32	77	6	6	6
Omicron BA.2	29	61	124	179	214	244	273	190	144	117	118	151
Delta	98	58	21	8	2	5	1	0	1	0	0	0

## Supplementary Table S2. Classification of comorbidities.

I10-I15, I20-I25, I42-I43					
150, 160-169					
J81					
E10, E11, E66					
K70.X, K74.3-K74.6, K75.4,					
K76.0					
N18.5, N18.9					
DR016, DR024					
A15-A19					
E84					
126, 127					
J42, J43, J44, J45, J47, J84					
J96, J98.2, J98.3					
G00-G99					
F00-F03					
C00-C99					
KAS, FQA, FQB, JJC, GDG, JLE					
DR046, DR047, DR048					
D80.0-D80.1					
D80.5, D81, D82, D83					
B20-B24					
D56, D57					
F10-F19, F30-F39, F20-F29					
Q90					

<sup>&</sup>lt;sup>a</sup> Swedish classification of certain interventions during health care visits

**Supplementary Table S3.** Vaccine effectiveness after at least three or two doses against severe COVID-19 in each follow up period. Estimates were obtained from conditional logistic regression for age and sex matched case and controls (1:10), and with adjustment for comorbidities  $(0, 1, \ge 2)$  and infection at least 90 days prior the case date. Results are presented overall and stratified by age, sex and comorbidities.

	Follow up period					
	Omicron BA.1	Transition	Omicron BA.2			
	2021 w52-2022 w1	2022 w2-3	2022 w4-11			
	VE (95% CI) <sup>a</sup>	VE (95% CI) <sup>a</sup>	VE (95% CI) <sup>a</sup>			
At least three doses						
All	94 (84 – 98)	90 (82 – 95)	82 (64 – 91)			
Age						
< 65 years	92 (73 – 98)	74 (16 – 92)	76(32-91)			
≥ 65 years	94 (76 – 98)	92 (83 – 97)	82(56-93)			
Sex						
Females	92 (74 – 97)	93 (81 – 98)	78(35-93)			
Males	96 (79 – 100)	89 (74 – 96)	84(62-93)			
Comorbidities						
None	99 (53 – 100)	96 (81 – 100)	77(27-92)			
≥1	90 (44 – 98)	84 (54 – 95)	85 (48 – 96)			
Two doses						
All	90 (78 – 95)	70 (42 – 84)	54 (13 – 75)			
Age						
< 65 years	93 (81 – 98)	78 (35 – 93)	59(4-83)			
≥ 65 years	84 (37 – 96)	55 (0 – 81)	43(0-79)			
Sex						
Females	88 (65 – 96)	73 (37 – 88)	53(0-82)			
Males	92 (73 – 98)	67 (14 – 87)	54(0-80)			
Comorbidities						
None	96 (66 – 100)	79 (32 – 94)	61(2-85)			
≥ 1	77 (0 – 95)	58 (0 – 86)	46(0-86)			

<sup>&</sup>lt;sup>a</sup>Vaccine effectiveness (95% confidence interval)